<DOC>
	<DOCNO>NCT01211847</DOCNO>
	<brief_summary>Once day oral administration DCCR help low triglyceride</brief_summary>
	<brief_title>Efficacy Study Diazoxide Choline Treat Hypertriglyceridemia</brief_title>
	<detailed_description>The population consist Statin-naive Statin-treated subject , without diabetes mellitus , fast triglyceride level range ≥ 500 mg/dL &lt; 1500 mg/dL . Subjects randomly assign 1 2 treatment group : DCCR Placebo Approximately 44 subject enrol study stratify Statin use 1:1 ratio treatment group ,</detailed_description>
	<mesh_term>Dyslipidemias</mesh_term>
	<mesh_term>Hypertriglyceridemia</mesh_term>
	<mesh_term>Fenofibrate</mesh_term>
	<mesh_term>Choline</mesh_term>
	<mesh_term>Diazoxide</mesh_term>
	<criteria>INCLUSION CRITERIA : Fasting triglyceride Difference Visit 3 ( 7 day prior Baseline Visit ) Visit 4 ( 3 day prior Baseline Visit ) ≤ 60 % ( compare high value Visit 3 Visit 4 ) Runin Triglycerides* ≥ 500 mg/dL &lt; 1500 mg/dL *Runin Triglyceride define average fasting triglyceride Visit 3 ( 7 day prior Baseline Visit ) Visit 4 ( 3 day prior Baseline Visit ) . Statin use • Either Statinnaive Must statin Screening remain Runin/Washout Period throughout study • Or Statintreated Must Lipitor 20 mg initiate start Runin/Washout Period continue throughout study Medication washout All subject must willing undergo washout lipidlowering medication Glycemic status Fasting glucose &lt; 126 mg/dL Screening Visit HbA1c &lt; 6.5 % Screening Visit EXCLUSION CRITERIA : Medications : recent , current , anticipated Administration investigational drug within 1 month prior Screening Visit Thyroid hormone preparation within 1 month prior Screening Visit ( except subject stable dose replacement therapy least 1 month ) Thiazide diuretic within 2 week prior Screening Visit Discontinuation betablockers within 1 month prior Screening Visit plan discontinuation betablocker therapy Anticipated requirement use prohibit concomitant medication History allergic reaction significant intolerance : Diazoxide Thiazides Sulfonamides Fenofibrate fenofibric acid derivative Lifestyle change • Subjects intend change exercise habit , quit smoking and/or quit alcohol use entire study Specific diagnose , medical condition history Known type I III hyperlipidemia Known type 1 DM Current diagnosis type 2 DM Any clinically significant endocrine , cardiovascular , pulmonary , neurological , psychiatric , hepatic , gastrointestinal , hematological , renal , dermatological disease interfere assessment study medication , accord Investigator Specific laboratory test result • Any relevant biochemical abnormality interfere assessment study medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>triglyceride</keyword>
	<keyword>Apo B</keyword>
	<keyword>non-HDL</keyword>
	<keyword>statin</keyword>
	<keyword>fenofibrate</keyword>
</DOC>